首页 | 本学科首页   官方微博 | 高级检索  
     

糖脉康颗粒联合格列美脲治疗2型糖尿病的临床研究
引用本文:永佳,王雅楠,永雪薇. 糖脉康颗粒联合格列美脲治疗2型糖尿病的临床研究[J]. 现代药物与临床, 2019, 34(7): 2156-2159
作者姓名:永佳  王雅楠  永雪薇
作者单位:乌鲁木齐市友谊医院 老年医学科/特需病房,新疆 乌鲁木齐,830049;乌鲁木齐市友谊医院 中医科,新疆 乌鲁木齐,830049;伊犁哈萨克自治州友谊医院 药剂科,新疆 伊犁,835000
摘    要:目的探究糖脉康颗粒联合格列美脲片治疗2型糖尿病的临床疗效。方法选取2016年5月—2017年9月乌鲁木齐市友谊医院收治的102例2型糖尿病患者为研究对象,全部患者随机分为对照组和治疗组,每组各51例。对照组早餐前服用格列美脲片,1~4 mg/d;治疗组在对照组基础上口服糖脉康颗粒,5 g/次,3次/d。两组均连续治疗8周。观察两组的临床疗效,比较两组的血糖水平、血脂水平和炎症指标。结果治疗后,对照组和治疗组的总有效率分别为76.47%、92.16%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者空腹血糖(FPG)、餐后2 h血糖(2 h PBG)和糖化血红蛋白(HbA1c)水平显著降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组FPG、2 h PBG、HbA1c水平明显低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平显著降低,高密度脂蛋白胆固醇(HDL-C)水平明显升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗组TG、TC、LDL-C水平较对照组明显下降,HDL-C水平较对照组明显上升,同组治疗前后比较差异有统计学意义(P0.05)。治疗后,两组患者hs-CRP、IL-6水平均明显下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组hs-CRP、IL-6水平明显低于对照组,两组比较差异有统计学意义(P0.05)。结论糖脉康颗粒联合格列美脲片治疗2型糖尿病具有较好的临床疗效,可改善其血糖血脂水平,降低炎症反应,具有一定的临床应用价值。

关 键 词:糖脉康颗粒  格列美脲片  2型糖尿病  血糖指标  血脂水平  炎症指标
收稿时间:2018-10-31

Clinical study on Tangmaikang Granules combined with glimepiride in treatment of type 2 diabetes
YONG Ji,WANG Ya-nan and YONG Xue-wei. Clinical study on Tangmaikang Granules combined with glimepiride in treatment of type 2 diabetes[J]. Drugs & Clinic, 2019, 34(7): 2156-2159
Authors:YONG Ji  WANG Ya-nan  YONG Xue-wei
Affiliation:Department of Geriatrics/Special Hospital Ward, Urumqi Friendship Hospital, Urumqi 8300492, China,Department of Traditional Chinese Medicine, Urumqi Friendship Hospital, Urumqi 8300492, China and Department of Pharmacy, Friendship Hospital of Yili Kazak Autonomous Prefecture, Yili 835000, China
Abstract:Objective To explore the clinical effect of Tangmaikang Granules combined with Glimepiride Tablets in treatment of type 2 diabetes. Methods Patients (102 cases) with type 2 diabetes in Urumqi Friendship Hospital from May 2016 to September 2017 were randomly divided into control and treatment groups, and each group had 51 cases. Patients in the control group were po administered with Glimepiride Tablets before breakfast, 1-4 mg/d. Patients in the treatment group were po administered with Tangmaikang Granules on the basis of the control group, 5 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and blood glucose level, blood lipid level, and inflammatory indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 76.47% and 92.16%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of FPG, 2 h PBG, and HbA1c in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the blood glucose levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of TG, TC, and LDL-C in two groups were significantly decreased, but the levels of HDL-C in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the blood lipid levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of hs-CRP and IL-6 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the inflammatory indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Tangmaikang Granules combined with Glimepiride Tablets has clinical curative effect in treatment of type 2 diabetes, can improve the level of blood sugar and lipid, and reduce the inflammatory reaction, which has a certain clinical application value.
Keywords:Tangmaikang Granules  Glimepiride Tablets  type 2 diabetes  blood glucose index  blood lipid level  inflammation index
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号